HMS
NRIX icon

Hanseatic Management Services’s Nurix Therapeutics NRIX Stock Holding History

Hanseatic Management Services’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$5.63K Hold
299
– – 0.01% 109
2024
Q3 		$6.72K Buy
+299
New +$6.77K 0.01% 100

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hanseatic Management Services's NRIX Position: Q4 2024 in Review

Hanseatic Management Services held its Nurix Therapeutics (NRIX) position steady in Q4 2024 at 299 shares worth $5.63K. The position accounts for 0.01% of the portfolio, ranked #109.

Hanseatic Management Services first reported a position in NRIX in Q3 2024 and has held it in 2 quarters since. The position peaked at $6.72K in Q3 2024. 175 funds tracked by Wall St. Rank hold NRIX as of Q4 2024.

  • Hanseatic Management Services held 299 shares of Nurix Therapeutics worth $5.63K as of Q4 2024.
  • Hanseatic Management Services left its Nurix Therapeutics share count unchanged in Q4 2024.
  • Nurix Therapeutics made up 0.01% of Hanseatic Management Services's portfolio in Q4 2024, its #109 holding.
  • Hanseatic Management Services first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • Hanseatic Management Services's Nurix Therapeutics position peaked at $6.72K in Q3 2024.
  • 175 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2024.

Based on Hanseatic Management Services's 13F filing for Q4 2024, filed 15 Jan 2025.